Leveraging Signaling Networks to Identify & Therapeutically Target Disease-Relevant Pathways in ADPKD

• Identifying and validating disease-driving signaling pathways across rare and genetic kidney diseases
• Evaluating strategies to therapeutically modulate dysregulated pathways, including inhibition, activation, and allosteric regulation
• Understanding how targeting different points in a signaling cascade influences disease progression and treatment outcomes

Speakers:

Adele Rowley

Chief Scientific Officer

Mironid